Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist

Add time:08/20/2019    Source:sciencedirect.com

Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure–activity relationship (SAR) study and ADME properties are presented.

We also recommend Trading Suppliers and Manufacturers of 4-(4-Hydroxybutyl)benzoic acid Methyl ester (cas 123910-88-3). Pls Click Website Link as below: cas 123910-88-3 suppliers

Prev:Benzoic acid glucosinolate esters and other glucosinolates from Arabidopsis thaliana
Next:Synthesis of novel glycosyl-1,2,3-1H-triazolyl methyl quinazolin-4(3H)-ones and their effect on GLUT4 translocation)